H.R. 10857 To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
Latest: Oct 22, 2026 · Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
What it means
Our plain-English summary and constitutional analysis for this bill is not published yet. Every analysis is reviewed by an editor before it appears here.
How they voted
No recorded floor votes yet.
Where it stands
Oct 22, 2026 · House
Sent to committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 22, 2026
Introduced
Introduced in House
Full official history (2 actions)
- Oct 22, 2026HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Oct 22, 2026Introduced in House
Supporters and opponents
No documented positions yet. Every position we list links to its public source.